ValuEngine downgraded shares of Tonix Pharmaceuticals (NASDAQ:TNXP) from a sell rating to a strong sell rating in a research note released on Sunday morning.
Separately, Aegis reissued a buy rating on shares of Tonix Pharmaceuticals in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $8.33.
Shares of Tonix Pharmaceuticals (TNXP) traded down $0.09 during mid-day trading on Friday, reaching $3.61. 46,200 shares of the company’s stock traded hands, compared to its average volume of 57,450. The firm has a market cap of $28.16, a price-to-earnings ratio of -1.07 and a beta of 2.62. Tonix Pharmaceuticals has a 52 week low of $2.85 and a 52 week high of $9.40.
A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. B. Riley Financial Inc. purchased a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 378,138 shares of the company’s stock, valued at approximately $1,637,000. B. Riley Financial Inc. owned about 5.05% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 17.57% of the company’s stock.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company?s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.